Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs